What is Lucid Diagnostics' operating income?

Lucid Diagnostics' total operating income in 2025 was -$49.64 million, based on the following breakdown: Total Gross Profit: -$1.96 million Total Operating Expenses: $47.68 million

Lucid Diagnostics (LUCD) Financials

$0.99 +0.02 (+2.31%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.59%)

As of 07/9/2026 07:35 PM Eastern

Compare

Annual Income Statements for Lucid Diagnostics

This table shows Lucid Diagnostics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-8.28	-28	-56	-53	-53	-71
Consolidated Net Income / (Loss)	-8.28	-28	-56	-53	-46	-58
Net Income / (Loss) Continuing Operations	-8.28	-28	-56	-53	-46	-58
Total Pre-Tax Income	-8.28	-28	-56	-53	-46	-58
Total Operating Income	-8.28	-27	-56	-48	-46	-50
Total Gross Profit	0.00	0.50	0.38	2.43	-2.75	-1.96
Total Revenue	0.00	0.50	0.38	2.43	4.35	4.71
Operating Revenue	0.00	0.50	0.38	2.43	4.35	4.71
Total Cost of Revenue	0.00	0.00	0.00	0.00	7.10	6.67
Operating Cost of Revenue	0.00	-	-	-	7.10	6.67
Total Operating Expenses	8.28	28	57	51	43	48
Selling, General & Admin Expense	1.53	13	24	19	20	24
Marketing Expense	1.31	5.26	16	16	16	18
Research & Development Expense	5.44	9.30	11	7.25	5.99	5.68
Amortization Expense	-	0.00	1.65	2.02	0.69	0.42
Total Other Income / (Expense), net	0.00	-0.66	0.16	-4.20	0.52	-8.37
Interest Expense	0.00	0.66	0.01	0.44	5.19	0.02
Interest & Investment Income	-	-	0.09	0.42	0.32	0.39
Other Income / (Expense), net	-	-	0.08	-4.18	5.39	-8.73
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock Dividends Declared	-	-	-	0.00	7.50	13
Basic Earnings per Share	($0.59)	($1.51)	($1.55)	($1.26)	($1.05)	($0.69)
Weighted Average Basic Shares Outstanding	14.11M	18.60M	36.17M	41.76M	50.52M	101.95M
Weighted Average Diluted Shares Outstanding	14.11M	18.60M	36.17M	41.76M	90.75M	176.95M
Weighted Average Basic & Diluted Shares Outstanding	14.11M	18.60M	43.39M	48.24M	90.75M	176.95M

This table shows Lucid Diagnostics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-14	-11	-18	-11	-12	-12	-36	-7.89	-10	-16	-24
Consolidated Net Income / (Loss)	-14	-11	-11	-11	-12	-12	-27	-4.44	-10	-16	-14
Net Income / (Loss) Continuing Operations	-14	-11	-11	-11	-12	-12	-27	-4.44	-10	-16	-14
Total Pre-Tax Income	-14	-11	-11	-11	-12	-12	-27	-4.44	-10	-16	-14
Total Operating Income	-11	-11	-11	-11	-12	-12	-12	-11	-12	-14	-12
Total Gross Profit	0.78	1.04	1.00	0.98	1.17	1.20	-0.72	1.16	1.21	-5.17	-0.37
Total Revenue	0.78	1.04	1.00	0.98	1.17	1.20	0.83	1.16	1.21	1.50	1.26
Operating Revenue	0.78	1.04	1.00	0.98	1.17	1.20	0.83	1.16	1.21	1.50	1.26
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	1.55	0.00	0.00	6.67	1.63
Operating Cost of Revenue	-	-	-	-	-	-	1.55	-	-	-	1.63
Total Operating Expenses	12	12	12	12	13	14	12	13	13	8.84	12
Selling, General & Admin Expense	4.32	4.20	4.07	4.87	5.36	5.86	6.16	5.62	5.61	6.48	5.43
Marketing Expense	3.84	4.41	4.19	4.21	4.06	4.00	4.07	4.01	4.29	5.34	5.00
Research & Development Expense	1.62	1.92	1.50	1.37	1.67	1.45	1.43	1.26	1.27	1.72	1.21
Amortization Expense	0.51	0.51	0.37	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11
Total Other Income / (Expense), net	-3.14	0.71	0.18	0.19	-0.68	0.83	-14	6.95	1.46	-2.41	-1.80
Interest Expense	0.18	0.01	0.18	0.52	0.44	4.06	0.01	0.01	0.00	0.01	0.01
Interest & Investment Income	0.12	0.09	0.07	0.11	0.08	0.07	0.07	0.11	0.10	0.11	0.07
Other Income / (Expense), net	-3.08	0.62	0.29	0.60	-0.32	4.83	-14	6.84	1.36	-2.52	-1.86
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Preferred Stock Dividends Declared	0.00	-	7.50	0.00	0.00	-	9.11	3.45	0.00	-	9.72
Basic Earnings per Share	($0.34)	($0.25)	($0.40)	($0.23)	($0.25)	($0.17)	($0.52)	($0.08)	($0.10)	$0.01	($0.17)
Weighted Average Basic Shares Outstanding	41.86M	41.76M	45.01M	48.21M	50.37M	50.52M	68.80M	98.99M	108.18M	101.95M	140.10M
Weighted Average Diluted Shares Outstanding	41.86M	41.76M	45.01M	48.21M	50.37M	50.52M	108.19M	98.99M	108.18M	176.95M	203.07M
Weighted Average Basic & Diluted Shares Outstanding	44.67M	48.24M	52.11M	53.99M	59.34M	90.75M	108.19M	108.48M	137.68M	176.95M	203.07M

This table details how cash moves in and out of Lucid Diagnostics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.05	54	-31	-3.58	3.46	12
Net Cash From Operating Activities	-5.63	-18	-30	-33	-44	-46
Net Cash From Continuing Operating Activities	-5.63	-18	-30	-33	-44	-46
Net Income / (Loss) Continuing Operations	-8.28	-28	-56	-53	-46	-58
Consolidated Net Income / (Loss)	-8.28	-28	-56	-53	-46	-58
Depreciation Expense	0.00	0.00	1.94	2.50	1.17	0.87
Non-Cash Adjustments To Reconcile Net Income	2.43	9.60	16	12	-0.37	13
Changes in Operating Assets and Liabilities, net	0.22	0.81	8.91	5.68	0.24	-2.82
Net Cash From Investing Activities	0.00	-0.86	-4.11	-0.22	-0.65	-0.20
Net Cash From Continuing Investing Activities	0.00	-0.86	-4.11	-0.22	-0.65	-0.20
Purchase of Property, Plant & Equipment	0.00	0.00	-3.20	-	-0.30	-0.20
Acquisitions	-	-	-	0.00	-0.35	0.00
Net Cash From Financing Activities	5.58	72	2.61	29	48	59
Net Cash From Continuing Financing Activities	5.58	72	2.61	29	48	59
Repayment of Debt	-	-	-	0.00	-3.62	0.00
Issuance of Debt	5.58	7.74	0.00	10	22	0.36
Issuance of Preferred Equity	-	-	0.00	19	30	0.00
Issuance of Common Equity	0.00	70	1.92	0.55	0.45	59
Other Financing Activities, net	0.01	0.00	0.70	0.28	0.00	0.02

This table details how cash moves in and out of Lucid Diagnostics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-8.52	-5.15	5.87	0.15	-10	7.87	2.88	5.89	16	-13	-6.83
Net Cash From Operating Activities	-8.78	-9.98	-13	-11	-10	-9.87	-12	-11	-11	-13	-12
Net Cash From Continuing Operating Activities	-8.76	-10	-13	-11	-10	-9.97	-13	-11	-11	-13	-12
Net Income / (Loss) Continuing Operations	-14	-11	-11	-11	-12	-12	-27	-4.44	-10	-16	-14
Consolidated Net Income / (Loss)	-14	-11	-11	-11	-12	-12	-27	-4.44	-10	-16	-14
Depreciation Expense	0.63	0.63	0.50	0.23	0.22	0.22	0.22	0.22	0.22	0.21	0.22
Non-Cash Adjustments To Reconcile Net Income	4.32	0.40	0.83	1.21	2.12	0.40	16	-5.62	-0.02	3.54	3.29
Changes in Operating Assets and Liabilities, net	0.50	-0.20	-3.33	-1.91	-0.14	0.95	-1.37	-0.71	-0.69	-0.06	-1.70
Net Cash From Investing Activities	-0.01	-0.18	-0.04	-	-0.35	-0.26	-0.09	-0.03	-0.03	-0.05	-0.22
Net Cash From Continuing Investing Activities	-0.01	-0.18	-0.04	-	-0.35	-0.26	-0.09	-0.03	-0.03	-0.05	-0.22
Purchase of Property, Plant & Equipment	-	-	-	-	-	-	-0.09	-	-	-	-0.22
Net Cash From Financing Activities	0.28	5.00	19	12	0.09	18	15	16	27	0.00	5.49
Net Cash From Continuing Financing Activities	0.28	5.00	19	12	0.09	18	15	16	27	0.00	5.49
Issuance of Debt	-	-	0.00	-	-	22	0.36	-	-	-	0.00
Issuance of Common Equity	0.28	-	0.35	-	0.09	-	15	16	27	0.27	5.48
Other Financing Activities, net	-	-	0.00	-	-	-	0.00	0.28	0.00	-0.27	0.00

This table presents Lucid Diagnostics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2.20	59	33	27	31	40
Total Current Assets	1.44	57	24	22	25	37
Cash & Equivalents	0.11	54	22	19	22	35
Accounts Receivable	0.00	0.20	0.02	0.05	0.05	0.64
Inventories, net	-	-	0.11	0.28	0.34	0.35
Prepaid Expenses	1.33	3.45	1.75	2.85	2.40	1.77
Plant, Property, & Equipment, net	0.00	0.97	1.59	1.33	1.06	0.81
Total Noncurrent Assets	0.76	0.73	6.56	3.86	4.51	2.17
Intangible Assets	-	0.00	3.45	1.42	0.74	0.32
Other Noncurrent Operating Assets	0.76	0.73	3.12	2.44	3.77	1.85
Total Liabilities & Shareholders' Equity	2.20	59	33	27	31	40
Total Liabilities	16	4.26	9.46	30	25	30
Total Current Liabilities	2.45	4.26	8.43	29	24	29
Short-Term Debt	-	-	0.00	14	19	24
Accounts Payable	2.06	2.60	2.50	4.99	1.24	0.97
Accrued Expenses	0.39	-	-	-	2.83	2.72
Other Current Liabilities	-	1.66	5.92	10	0.85	0.89
Total Noncurrent Liabilities	13	0.00	1.04	0.20	1.80	0.93
Other Noncurrent Operating Liabilities	13	0.00	1.04	0.20	1.80	0.93
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-14	55	23	-2.31	5.39	11
Total Preferred & Common Equity	-14	55	23	-2.31	5.39	11
Preferred Stock	0.00	0.00	0.00	19	54	54
Total Common Equity	-14	55	23	-21	-49	-43
Common Stock	0.31	97	121	130	155	231
Retained Earnings	-14	-42	-98	-151	-204	-274

This table presents Lucid Diagnostics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	33	32	34	23	33	39	53	34
Total Current Assets	27	28	28	17	28	34	50	31
Cash & Equivalents	24	25	25	14	25	31	47	28
Accounts Receivable	0.02	0.05	0.16	0.04	0.06	0.37	0.55	0.69
Inventories, net	-	0.41	0.68	0.65	0.48	0.51	0.49	0.47
Prepaid Expenses	3.23	2.36	2.18	1.65	1.75	1.83	1.47	2.33
Plant, Property, & Equipment, net	1.28	1.24	1.05	0.94	1.04	0.95	0.86	0.91
Total Noncurrent Assets	4.66	3.22	5.12	4.83	4.22	3.89	2.49	1.81
Intangible Assets	1.93	1.05	0.95	0.84	0.63	0.53	0.42	0.21
Other Noncurrent Operating Assets	2.73	2.17	4.17	3.99	3.59	3.36	2.07	1.60
Total Liabilities & Shareholders' Equity	33	32	34	23	33	39	53	34
Total Liabilities	31	20	18	16	38	31	27	30
Total Current Liabilities	30	20	16	14	37	29	26	29
Short-Term Debt	14	13	11	10	33	25	22	25
Accounts Payable	4.32	4.11	3.63	3.14	2.90	3.26	3.03	1.08
Accrued Expenses	-	-	-	-	-	-	-	2.20
Other Current Liabilities	11	2.73	1.15	0.91	0.87	0.87	0.88	0.91
Total Noncurrent Liabilities	0.46	0.18	2.15	2.01	1.60	1.38	1.16	0.70
Other Noncurrent Operating Liabilities	0.46	0.18	2.15	2.01	1.60	1.38	1.16	0.70
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2.56	12	16	6.34	-5.38	7.86	26	4.00
Total Preferred & Common Equity	2.56	12	16	6.34	-5.38	7.86	26	4.00
Preferred Stock	14	44	56	56	54	54	54	10
Total Common Equity	-11	-32	-40	-50	-60	-47	-28	-6.13
Common Stock	129	136	140	143	180	201	230	292
Retained Earnings	-140	-169	-180	-192	-240	-248	-258	-298

This table displays calculated financial ratios and metrics derived from Lucid Diagnostics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	36,808,647.00	39,108,245.00	44,667,304.00	-	137,683,002.00
DEI Adjusted Shares Outstanding	0.00	36,808,647.00	39,108,245.00	44,667,304.00	-	137,683,002.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-0.76	-1.44	-1.18	-	-0.51
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	-24.60%	544.03%	79.00%	8.28%
EBITDA Growth	0.00%	-231.10%	-97.83%	7.50%	21.28%	-45.61%
EBIT Growth	0.00%	-231.15%	-104.86%	6.24%	22.80%	-43.57%
NOPAT Growth	0.00%	-231.15%	-105.15%	13.81%	5.01%	-7.79%
Net Income Growth	0.00%	-239.11%	-100.05%	6.24%	13.55%	-27.41%
EPS Growth	0.00%	0.00%	0.00%	18.71%	16.67%	0.00%
Operating Cash Flow Growth	0.00%	-213.87%	-68.02%	-10.55%	-34.50%	-5.31%
Free Cash Flow Firm Growth	0.00%	0.00%	-14.63%	32.83%	-57.53%	18.92%
Invested Capital Growth	0.00%	107.95%	-47.09%	-1,366.49%	122.50%	-85.85%
Revenue Q/Q Growth	0.00%	0.00%	-33.27%	61.87%	3.75%	6.98%
EBITDA Q/Q Growth	0.00%	0.00%	-5.94%	7.58%	6.79%	-18.53%
EBIT Q/Q Growth	0.00%	0.00%	-6.96%	7.22%	7.47%	-18.18%
NOPAT Q/Q Growth	0.00%	0.00%	-7.11%	6.77%	-2.04%	-3.41%
Net Income Q/Q Growth	0.00%	0.00%	-6.89%	7.22%	-1.59%	-8.87%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	7.08%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	-86.63%	15.92%	-21.11%	0.24%	-6.18%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	9.35%	-1.19%	-3.06%
Invested Capital Q/Q Growth	0.00%	0.00%	-4.34%	-3.61%	-20.30%	-71.23%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	-41.73%
EBITDA Margin	0.00%	-5,483.00%	-14,385.94%	-2,066.19%	-908.67%	-1,221.89%
Operating Margin	0.00%	-5,483.80%	-14,920.69%	-1,996.79%	-1,059.64%	-1,054.82%
EBIT Margin	0.00%	-5,483.80%	-14,899.47%	-2,169.11%	-935.53%	-1,240.42%
Profit (Net Income) Margin	0.00%	-5,615.60%	-14,899.47%	-2,169.11%	-1,047.61%	-1,232.68%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	102.40%	100.00%	100.00%	111.98%	99.38%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-4,755.52%	0.00%	0.00%	-3,728.33%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-4,711.40%	0.00%	0.00%	-3,406.65%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	4,611.09%	0.00%	0.00%	3,017.72%
Return on Equity (ROE)	61.25%	-136.23%	-144.42%	-507.97%	-2,956.43%	-710.60%
Cash Return on Invested Capital (CROIC)	0.00%	-3,130.68%	-4,693.93%	0.00%	-2,518.46%	-3,577.90%
Operating Return on Assets (OROA)	0.00%	-89.61%	-122.77%	-176.20%	-140.24%	-164.06%
Return on Assets (ROA)	0.00%	-91.77%	-122.77%	-176.20%	-157.04%	-163.04%
Return on Common Equity (ROCE)	61.25%	-136.23%	-144.42%	-51.71%	67,157.00%	4,020.06%
Return on Equity Simple (ROE_SIMPLE)	61.25%	-51.29%	-243.72%	2,278.93%	-844.54%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.80	-19	-39	-34	-32	-35
NOPAT Margin	0.00%	-3,838.66%	-10,444.48%	-1,397.75%	-741.75%	-738.38%
Net Nonoperating Expense Percent (NNEP)	-2,237.84%	-33.05%	-44.12%	-136.61%	-305.44%	-321.68%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-291.58%	-134.37%	-99.46%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	141.73%
SG&A Expenses to Revenue	0.00%	2,555.60%	6,359.15%	793.00%	463.78%	507.16%
R&D to Revenue	0.00%	1,859.20%	2,985.94%	298.68%	137.87%	120.65%
Operating Expenses to Revenue	0.00%	5,583.80%	15,020.69%	2,096.79%	1,159.64%	1,013.09%
Earnings before Interest and Taxes (EBIT)	-8.28	-27	-56	-53	-41	-58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-8.28	-27	-54	-50	-39	-58
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.61	2.31	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	3.61	2.71	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	395.32	141.08	25.94	11.18	63.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	132.97	53.60	0.00	60.77	1,487.14
Enterprise Value to Revenue (EV/Rev)	0.00	288.01	81.47	31.57	22.84	73.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	-6.04	3.45	2.19
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.01	-1.30	-0.98	-1.32	-2.83	-0.89
Leverage Ratio	-0.16	1.48	1.18	2.88	18.83	4.36
Compound Leverage Factor	-0.16	1.52	1.18	2.88	21.08	4.33
Debt to Total Capital	0.00%	0.00%	0.00%	119.86%	77.53%	68.70%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	119.86%	77.53%	68.70%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	160.02%	226.83%	155.35%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	-179.88%	-204.36%	-124.05%
Debt to EBITDA	0.00	0.00	0.00	-0.28	-0.47	-0.42
Net Debt to EBITDA	0.00	0.00	0.00	0.10	0.10	0.19
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	-0.41	-0.58	-0.69
Net Debt to NOPAT	0.00	0.00	0.00	0.15	0.12	0.31
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-19.15	26.40	-5.95	-13.07	-12.30	-7.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	89.82%	2,371.56%	665.73%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.59	13.45	2.89	0.75	1.07	1.31
Quick Ratio	0.05	12.64	2.67	0.64	0.95	1.24
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-34	-39	-26	-41	-33
Operating Cash Flow to CapEx	0.00%	0.00%	-927.66%	0.00%	0.00%	-23,596.45%
Free Cash Flow to Firm to Interest Expense	0.00	-51.45	-4,858.21	-59.07	-7.92	-1,515.73
Operating Cash Flow to Interest Expense	0.00	-26.81	-3,710.63	-74.25	-8.50	-2,112.95
Operating Cash Flow Less CapEx to Interest Expense	0.00	-26.81	-4,110.63	-74.25	-8.50	-2,121.91
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.02	0.01	0.08	0.15	0.13
Accounts Receivable Turnover	0.00	0.00	3.47	78.32	96.58	13.68
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	19.22
Fixed Asset Turnover	0.00	0.00	0.29	1.66	3.63	5.03
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	6.03
Days Sales Outstanding (DSO)	0.00	0.00	105.05	4.66	3.78	26.68
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	18.99
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	60.50
Cash Conversion Cycle (CCC)	0.00	0.00	105.05	4.66	3.78	-14.83
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-14	1.08	0.57	-7.26	1.63	0.23
Invested Capital Turnover	0.00	-0.08	0.46	-0.73	-1.55	5.05
Increase / (Decrease) in Invested Capital	0.00	15	-0.51	-7.83	8.89	-1.40
Enterprise Value (EV)	70	144	31	77	99	344
Market Capitalization	70	198	53	63	49	300
Book Value per Share	($0.96)	$1.49	$0.59	($0.47)	($0.83)	($0.16)
Tangible Book Value per Share	($0.96)	$1.49	$0.50	($0.50)	($0.84)	($0.16)
Total Capital	-14	55	23	12	24	35
Total Debt	0.00	0.00	0.00	14	19	24
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-0.11	-54	-22	-4.95	-3.76	-11
Capital Expenditures (CapEx)	0.00	0.00	3.20	0.00	0.00	0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.12	-0.61	-6.54	-12	-2.13	-1.82
Debt-free Net Working Capital (DFNWC)	-1.01	53	16	6.64	20	33
Net Working Capital (NWC)	-1.01	53	16	-7.31	1.62	8.89
Net Nonoperating Expense (NNE)	2.48	8.88	17	19	13	23
Net Nonoperating Obligations (NNO)	-0.11	-54	-22	-4.95	-3.76	-11
Total Depreciation and Amortization (D&A)	0.00	0.00	1.94	2.50	1.17	0.87
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-122.60%	-1,735.54%	-504.74%	-49.10%	-38.65%
Debt-free Net Working Capital to Revenue	0.00%	10,608.60%	4,225.73%	273.52%	465.35%	698.81%
Net Working Capital to Revenue	0.00%	10,608.60%	4,225.73%	-301.03%	37.37%	188.82%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.51)	($1.55)	($1.26)	($1.05)	($0.69)
Adjusted Weighted Average Basic Shares Outstanding	0.00	37.43M	36.17M	41.76M	50.52M	101.95M
Adjusted Diluted Earnings per Share	$0.00	($1.51)	$0.00	($1.26)	($1.05)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	37.43M	43.39M	41.76M	50.52M	176.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.51)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	18.60M	43.39M	48.24M	90.75M	176.95M
Normalized Net Operating Profit after Tax (NOPAT)	-5.80	-19	-39	-34	-32	-35
Normalized NOPAT Margin	0.00%	-3,838.66%	-10,444.48%	-1,397.75%	-741.75%	-738.38%
Pre Tax Income Margin	0.00%	-5,615.60%	-14,899.47%	-2,169.11%	-1,047.61%	-1,232.68%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-41.61	-7,021.38	-119.15	-7.83	-2,653.36
NOPAT to Interest Expense	0.00	-29.12	-4,921.96	-76.78	-6.21	-1,579.45
EBIT Less CapEx to Interest Expense	0.00	-41.61	-7,421.38	-119.15	-7.83	-2,662.32
NOPAT Less CapEx to Interest Expense	0.00	-29.12	-5,321.96	-76.78	-6.21	-1,588.41
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Lucid Diagnostics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	43,725,703.00	44,667,304.00	48,244,798.00	52,114,353.00	53,990,294.00	-	90,958,695.00	108,411,028.00	137,508,926.00	137,683,002.00	176,945,972.00
DEI Adjusted Shares Outstanding	43,725,703.00	44,667,304.00	48,244,798.00	52,114,353.00	53,990,294.00	-	90,958,695.00	108,411,028.00	137,508,926.00	137,683,002.00	176,945,972.00
DEI Earnings Per Adjusted Shares Outstanding	-0.32	-0.24	-0.38	-0.21	-0.23	-	-0.40	-0.07	-0.08	-0.12	-0.13
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	930.26%	828.57%	124.44%	513.84%	49.68%	15.10%	-17.28%	19.16%	3.33%	25.65%	51.69%
EBITDA Growth	1.26%	28.73%	36.04%	3.57%	13.12%	28.18%	-167.44%	58.31%	13.76%	-122.73%	48.58%
EBIT Growth	0.98%	27.45%	35.37%	6.92%	15.43%	30.30%	-156.79%	57.11%	13.47%	-118.95%	48.18%
NOPAT Growth	22.60%	23.52%	24.62%	3.38%	-5.09%	-8.04%	-15.71%	-1.72%	-0.56%	-13.22%	2.99%
Net Income Growth	0.98%	27.45%	34.68%	3.30%	12.93%	-6.57%	-153.56%	59.66%	15.96%	-40.94%	48.31%
EPS Growth	12.82%	0.00%	0.00%	14.81%	26.47%	32.00%	0.00%	65.22%	60.00%	0.00%	0.00%
Operating Cash Flow Growth	-38.37%	-134.36%	-77.13%	-65.52%	-15.88%	1.08%	1.17%	8.13%	-7.06%	-27.42%	2.92%
Free Cash Flow Firm Growth	98.50%	98.12%	-20.63%	-1,290.76%	-9,138.37%	-9,280.97%	-1.19%	51.52%	59.48%	52.11%	28.54%
Invested Capital Growth	-1,269.28%	-1,366.49%	109.76%	138.36%	129.25%	122.50%	724.53%	-9.74%	-60.81%	-85.85%	-39.41%
Revenue Q/Q Growth	392.45%	32.82%	-3.75%	-2.50%	20.08%	2.13%	-30.83%	40.46%	4.13%	24.19%	-16.49%
EBITDA Q/Q Growth	-26.38%	24.90%	1.97%	-3.64%	-13.87%	37.92%	-265.06%	83.81%	-135.52%	-60.33%	15.73%
EBIT Q/Q Growth	-24.84%	23.78%	3.04%	-0.88%	-13.43%	37.18%	-257.25%	83.12%	-128.86%	-58.95%	15.45%
NOPAT Q/Q Growth	3.94%	-2.92%	5.77%	-3.71%	-4.49%	-5.81%	-0.91%	8.83%	-3.29%	-19.14%	13.53%
Net Income Q/Q Growth	-24.84%	23.78%	2.01%	-3.70%	-12.41%	6.71%	-133.15%	83.50%	-134.22%	-56.45%	14.49%
EPS Q/Q Growth	-25.93%	26.47%	-60.00%	42.50%	-8.70%	32.00%	0.00%	84.62%	-25.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-26.58%	-13.64%	-26.39%	8.96%	11.38%	2.99%	-26.28%	15.37%	-3.26%	-15.47%	3.79%
Free Cash Flow Firm Q/Q Growth	-113.90%	-0.27%	-5,530.89%	-51.70%	-7.86%	-1.82%	39.26%	27.32%	9.85%	-20.32%	9.35%
Invested Capital Q/Q Growth	-18.93%	-3.61%	103.65%	752.45%	-9.30%	-20.30%	33.80%	-6.68%	-60.62%	-71.23%	473.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-87.32%	100.00%	100.00%	-343.48%	-29.38%
EBITDA Margin	-1,734.74%	-980.87%	-999.00%	-1,061.89%	-1,006.91%	-612.03%	-3,229.95%	-371.54%	-840.38%	-1,084.91%	-1,094.82%
Operating Margin	-1,421.20%	-1,101.25%	-1,078.12%	-1,146.72%	-997.78%	-1,033.75%	-1,508.09%	-978.85%	-971.02%	-931.52%	-964.49%
EBIT Margin	-1,814.56%	-1,041.35%	-1,049.05%	-1,085.35%	-1,025.26%	-630.58%	-3,256.64%	-390.63%	-858.55%	-1,098.80%	-1,112.50%
Profit (Net Income) Margin	-1,814.56%	-1,041.35%	-1,060.14%	-1,127.56%	-1,055.55%	-964.16%	-3,249.76%	-381.69%	-858.55%	-1,081.52%	-1,107.40%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	101.06%	103.89%	102.95%	152.90%	99.79%	97.71%	100.00%	98.43%	99.54%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,596.15%	-1,390.16%	-2,096.81%	-3,292.49%	-1,975.60%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,702.76%	-1,426.28%	-2,082.04%	-3,203.17%	-2,197.83%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,686.69%	1,169.15%	1,897.47%	2,837.48%	7,798.55%
Return on Equity (ROE)	-377.31%	-507.97%	-255.60%	-300.52%	-1,007.83%	-2,956.43%	-1,909.47%	-221.00%	-199.34%	-455.01%	5,822.96%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-13,000.34%	-1,741.63%	-1,983.64%	-2,518.46%	-2,885.13%	-1,551.29%	-2,269.06%	-3,577.90%	-1,916.55%
Operating Return on Assets (OROA)	-76.01%	-84.59%	-77.10%	-107.69%	-153.82%	-94.52%	-419.17%	-46.80%	-99.66%	-145.33%	-170.81%
Return on Assets (ROA)	-76.01%	-84.59%	-77.92%	-111.87%	-158.36%	-144.53%	-418.28%	-45.73%	-99.66%	-143.05%	-170.03%
Return on Common Equity (ROCE)	-206.45%	-51.71%	146.62%	372.56%	6,872.57%	67,157.00%	27,010.59%	801.82%	483.39%	2,574.13%	278,799.96%
Return on Equity Simple (ROE_SIMPLE)	-2,220.81%	0.00%	-395.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.79	-8.02	-7.55	-7.83	-8.19	-8.66	-8.74	-7.97	-8.23	-9.81	-8.48
NOPAT Margin	-994.84%	-770.88%	-754.69%	-802.70%	-698.45%	-723.63%	-1,055.66%	-685.19%	-679.71%	-652.06%	-675.14%
Net Nonoperating Expense Percent (NNEP)	-35.18%	-20.52%	-15.58%	-18.28%	-60.44%	-66.16%	-893.39%	36.12%	-14.77%	-89.32%	222.24%
Return On Investment Capital (ROIC_SIMPLE)	-	-68.88%	-30.18%	-28.83%	-49.50%	-36.10%	-31.87%	-24.03%	-17.10%	-28.07%	-29.04%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	187.32%	0.00%	0.00%	443.48%	129.38%
SG&A Expenses to Revenue	551.72%	404.23%	406.59%	498.67%	456.91%	489.89%	744.20%	482.98%	462.84%	431.05%	432.48%
R&D to Revenue	206.26%	184.33%	149.95%	140.57%	142.15%	121.39%	172.46%	107.91%	105.04%	114.56%	96.02%
Operating Expenses to Revenue	1,521.20%	1,201.25%	1,178.12%	1,246.72%	1,097.78%	1,133.75%	1,420.77%	1,078.85%	1,071.02%	588.03%	935.11%
Earnings before Interest and Taxes (EBIT)	-14	-11	-11	-11	-12	-7.55	-27	-4.54	-10	-17	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-10	-10	-10	-12	-7.33	-27	-4.32	-10	-16	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	34.11	25.94	13.10	11.25	10.50	11.18	32.40	52.53	49.80	63.74	39.64
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	270.68	37.60	46.67	60.77	90.25	136.15	309.21	1,487.14	159.32
Enterprise Value to Revenue (EV/Rev)	36.82	31.57	24.05	22.35	22.83	22.84	47.26	63.67	56.44	73.00	41.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	5.67	-6.04	1.10	0.70	1.61	3.45	-6.10	3.22	0.86	2.19	6.30
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.21	-1.32	-1.07	-1.12	-1.56	-2.83	-0.62	-0.82	-0.91	-0.89	-3.55
Leverage Ratio	2.38	2.88	2.21	2.47	6.28	18.83	9.95	3.05	2.36	4.36	-48.57
Compound Leverage Factor	2.38	2.88	2.23	2.56	6.46	28.79	9.93	2.98	2.36	4.29	-48.34
Debt to Total Capital	85.01%	119.86%	52.49%	41.21%	61.68%	77.53%	119.61%	76.29%	46.33%	68.70%	86.30%
Short-Term Debt to Total Capital	85.01%	119.86%	52.49%	41.21%	61.68%	77.53%	119.61%	76.29%	46.33%	68.70%	86.30%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	79.93%	160.02%	176.90%	205.74%	338.12%	226.83%	198.44%	164.10%	112.75%	155.35%	34.71%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-64.94%	-179.88%	-129.39%	-146.95%	-299.80%	-204.36%	-218.05%	-140.39%	-59.08%	-124.05%	-21.01%
Debt to EBITDA	-0.27	-0.28	-0.30	-0.25	-0.24	-0.47	-0.58	-0.50	-0.46	-0.42	-0.57
Net Debt to EBITDA	0.18	0.10	0.26	0.31	0.10	0.10	-0.13	0.12	0.52	0.19	0.06
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.40	-0.41	-0.42	-0.36	-0.32	-0.58	-0.98	-0.75	-0.66	-0.69	-0.73
Net Debt to NOPAT	0.26	0.15	0.37	0.44	0.14	0.12	-0.23	0.17	0.74	0.31	0.08
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-6.36	-8.00	-6.92	-6.46	-11.72	-8.74	-11.03	-4.64	-2.02	-4.37	-9.31
Noncontrolling Interest Sharing Ratio	45.28%	89.82%	157.36%	223.97%	781.92%	2,371.56%	1,514.56%	462.81%	342.50%	665.73%	-4,687.94%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.90	0.75	1.38	1.75	1.18	1.07	0.75	1.15	1.90	1.31	1.07
Quick Ratio	0.80	0.64	1.24	1.57	1.02	0.95	0.69	1.07	1.83	1.24	0.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-0.19	-0.19	-11	-16	-17	-18	-11	-7.75	-6.99	-8.41	-7.62
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-13,403.23%	0.00%	0.00%	0.00%	-5,628.37%
Free Cash Flow to Firm to Interest Expense	-1.07	-17.01	-58.86	-30.79	-39.54	-4.32	-1,184.54	-1,291.47	-3,492.65	-1,681.00	-1,269.80
Operating Cash Flow to Interest Expense	-50.18	-907.18	-70.46	-22.12	-23.34	-2.43	-1,385.00	-1,758.17	-5,446.50	-2,515.60	-2,016.83
Operating Cash Flow Less CapEx to Interest Expense	-50.18	-907.18	-70.46	-22.12	-23.34	-2.43	-1,395.33	-1,758.17	-5,446.50	-2,515.60	-2,052.67
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.08	0.07	0.10	0.15	0.15	0.13	0.12	0.12	0.13	0.15
Accounts Receivable Turnover	57.69	78.32	78.50	38.97	139.63	96.58	75.87	16.36	14.94	13.68	13.69
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	19.35	0.00	0.00	19.22	14.15
Fixed Asset Turnover	1.08	1.66	2.17	3.12	3.77	3.63	3.66	4.36	4.88	5.03	5.27
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	2.47	0.00	0.00	6.03	3.39
Days Sales Outstanding (DSO)	6.33	4.66	4.65	9.37	2.61	3.78	4.81	22.31	24.44	26.68	26.66
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	18.86	0.00	0.00	18.99	25.79
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	147.84	0.00	0.00	60.50	107.68
Cash Conversion Cycle (CCC)	6.33	4.66	4.65	9.37	2.61	3.78	-124.16	22.31	24.44	-14.83	-55.23
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-7.00	-7.26	0.27	2.26	2.05	1.63	2.19	2.04	0.80	0.23	1.32
Invested Capital Turnover	-0.47	-0.73	-2.43	-2.09	-1.69	-1.55	3.41	2.03	3.08	5.05	2.93
Increase / (Decrease) in Invested Capital	-7.60	-7.83	2.98	8.15	9.05	8.89	1.92	-0.22	-1.25	-1.40	-0.86
Enterprise Value (EV)	55	77	72	85	96	99	197	278	248	344	211
Market Capitalization	51	63	39	43	44	49	135	229	219	300	203
Book Value per Share	($0.25)	($0.47)	($0.67)	($0.77)	($0.92)	($0.83)	($0.66)	($0.23)	($0.13)	($0.16)	($0.03)
Tangible Book Value per Share	($0.30)	($0.50)	($0.69)	($0.78)	($0.93)	($0.84)	($0.67)	($0.24)	($0.13)	($0.16)	($0.04)
Total Capital	17	12	25	27	17	24	27	33	48	35	29
Total Debt	14	14	13	11	10	19	33	25	22	24	25
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-9.56	-4.95	-12	-14	-4.29	-3.76	7.56	-5.82	-25	-11	-2.68
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.00	0.00	0.00	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	-12	-4.02	-1.75	-1.71	-2.13	-1.47	-1.42	-1.40	-1.82	-0.70
Debt-free Net Working Capital (DFNWC)	12	6.64	21	23	13	20	24	30	46	33	27
Net Working Capital (NWC)	-2.92	-7.31	7.61	12	2.58	1.62	-9.03	4.41	24	8.89	1.98
Net Nonoperating Expense (NNE)	6.42	2.81	3.06	3.17	4.19	2.88	18	-3.53	2.17	6.46	5.43
Net Nonoperating Obligations (NNO)	-9.56	-4.95	-12	-14	-4.29	-3.76	7.56	-5.82	-25	-11	-2.68
Total Depreciation and Amortization (D&A)	0.63	0.63	0.50	0.23	0.22	0.22	0.22	0.22	0.22	0.21	0.22
Debt-free, Cash-free Net Working Capital to Revenue	-832.07%	-504.74%	-134.86%	-46.13%	-40.92%	-49.10%	-35.23%	-32.48%	-31.73%	-38.65%	-13.62%
Debt-free Net Working Capital to Revenue	771.27%	273.52%	695.47%	609.66%	304.97%	465.35%	569.57%	681.35%	1,044.24%	698.81%	529.35%
Net Working Capital to Revenue	-194.73%	-301.03%	254.98%	314.92%	61.47%	37.37%	-216.44%	101.08%	537.30%	188.82%	38.51%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.34)	($0.25)	($0.40)	($0.23)	($0.25)	($0.17)	($0.52)	($0.08)	($0.10)	$0.01	($0.17)
Adjusted Weighted Average Basic Shares Outstanding	41.86M	41.76M	45.01M	48.21M	50.37M	50.52M	68.80M	98.99M	108.18M	101.95M	140.10M
Adjusted Diluted Earnings per Share	($0.34)	($0.25)	($0.40)	($0.23)	($0.25)	($0.17)	($0.52)	($0.08)	($0.10)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	41.86M	41.76M	45.01M	48.21M	50.37M	50.52M	68.80M	98.99M	108.18M	176.95M	203.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.67M	48.24M	52.11M	53.99M	59.34M	90.75M	108.19M	108.48M	137.68M	176.95M	203.07M
Normalized Net Operating Profit after Tax (NOPAT)	-7.79	-8.02	-7.55	-7.83	-8.19	-8.66	-8.74	-7.97	-8.23	-9.81	-8.48
Normalized NOPAT Margin	-994.84%	-770.88%	-754.69%	-802.70%	-698.45%	-723.63%	-1,055.66%	-685.19%	-679.71%	-652.06%	-675.14%
Pre Tax Income Margin	-1,814.56%	-1,041.35%	-1,060.14%	-1,127.56%	-1,055.55%	-964.16%	-3,249.76%	-381.69%	-858.55%	-1,081.52%	-1,107.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-81.19	-984.55	-58.66	-20.41	-27.56	-1.86	-2,996.11	-757.17	-5,198.50	-3,305.20	-2,328.83
NOPAT to Interest Expense	-44.51	-728.83	-42.20	-15.10	-18.77	-2.13	-971.21	-1,328.13	-4,115.65	-1,961.40	-1,413.30
EBIT Less CapEx to Interest Expense	-81.19	-984.55	-58.66	-20.41	-27.56	-1.86	-3,006.44	-757.17	-5,198.50	-3,305.20	-2,364.67
NOPAT Less CapEx to Interest Expense	-44.51	-728.83	-42.20	-15.10	-18.77	-2.13	-981.54	-1,328.13	-4,115.65	-1,961.40	-1,449.13
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Lucid Diagnostics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lucid Diagnostics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Lucid Diagnostics' net income appears to be on an upward trend, with a most recent value of -$58.01 million in 2025, rising from -$8.28 million in 2020. The previous period was -$45.53 million in 2024. View Lucid Diagnostics' forecast to see where analysts expect Lucid Diagnostics to go next.

Lucid Diagnostics' total operating income in 2025 was -$49.64 million, based on the following breakdown:

Total Gross Profit: -$1.96 million
Total Operating Expenses: $47.68 million

Over the last 5 years, Lucid Diagnostics' total revenue changed from $0.00 in 2020 to $4.71 million in 2025, a change of 470,600,000.0%.

Lucid Diagnostics' total liabilities were at $29.51 million at the end of 2025, a 16.5% increase from 2024, and a 87.8% increase since 2020.

In the past 5 years, Lucid Diagnostics' cash and equivalents has ranged from $111 thousand in 2020 to $53.66 million in 2021, and is currently $34.71 million as of their latest financial filing in 2025.

Over the last 5 years, Lucid Diagnostics' book value per share changed from -0.96 in 2020 to -0.16 in 2025, a change of -83.6%.

Related Companies

Financial statements for NASDAQ:LUCD last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Financials

Financials Breakdown Chart

Lucid Diagnostics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Financials

Annual Income Statements for Lucid Diagnostics

Quarterly Income Statements for Lucid Diagnostics

Annual Cash Flow Statements for Lucid Diagnostics

Quarterly Cash Flow Statements for Lucid Diagnostics

Annual Balance Sheets for Lucid Diagnostics

Quarterly Balance Sheets for Lucid Diagnostics

Annual Metrics And Ratios for Lucid Diagnostics

Quarterly Metrics And Ratios for Lucid Diagnostics

Financials Breakdown Chart

Lucid Diagnostics Financials - Frequently Asked Questions

When does Lucid Diagnostics' fiscal year end?

How has Lucid Diagnostics' net income changed over the last 5 years?

What is Lucid Diagnostics' operating income?

How has Lucid Diagnostics' revenue changed over the last 5 years?

How much debt does Lucid Diagnostics have?

How much cash does Lucid Diagnostics have?

How has Lucid Diagnostics' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools